Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × anlotinib × Gynecologic × Clear all

Phase

Phase 2 9 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Head & Neck 2 Sarcoma 1 Gynecologic 1 Endocrine 1

Conditions

Platinum-resistant Ovarian Cancer (PROC) 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 9 human papillomavirus vaccine, L1 type 16, 18 6 niraparib 4 Human Papillomavirus Recombinant Vaccine nonavalent 4 Vaccines 3 Saline Solution 3 Papillomavirus Vaccines 3 Carboplatin 3 pegylated granulocyte colony-stimulating factor 2 olaparib 2 liposomal doxorubicin 2 fluciclovine F-18 2 apatinib 2 Sevoflurane 2 Propofol 2 Paclitaxel 2 Medroxyprogesterone Acetate 2 Bevacizumab 2 Aspirin 2 pegfilgrastim 1 pazopanib 1 palbociclib 1 lenvatinib 1 ganirelix 1 gadofosveset trisodium 1 fosaprepitant 1 ferrous gluconate 1 ferrous fumarate 1 epoetin beta 1 dostarlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07075250 2025-07-20

RIFOC003

Peking University People's Hospital

Phase 4 Not yet recruiting

Platinum-resistant Ovarian Cancer (PROC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡